SCHEMBL15567968

SCHEMBL15567968

FC(F)(F)c1cccc(-c2c[nH]c(=S)[nH]2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
GAA P10253 1/20 0.56
GFER P55789 1/20 0.56
SCN2A Q99250 3/20 0.51
IDO1 P14902 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
NPY5R Q15761 1/20 0.45
XDH P47989 1/20 0.43
TYMP P19971 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CXCR2 P25025 1/20 0.41
MAPT P10636 1/20 0.40
HRH1 P35367 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
CDC7 O00311 1/20 0.40
HTR2C P28335 1/20 0.40
CTSS P25774 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3349475 0.80 HDAC8 (0.59) KDM4EGAAGFERSCN2AHDAC8
SCHEMBL3341441 0.78 GFER (0.61) KDM4EGAAGFERIDO1HDAC8
SCHEMBL638571 0.77 GFER (0.51) KDM4EGAAGFERHDAC8NPY5R
SCHEMBL3341447 0.75 KDM4E (0.61) KDM4EGAAGFERIDO1HDAC8
SCHEMBL639362 0.75 GFER (0.61) KDM4EGAAGFERIDO1HDAC8
SCHEMBL3344186 0.75 KDM4E (0.61) KDM4EGAAGFERSCN2AIDO1
SCHEMBL15568603 0.74 GFER (0.47) KDM4EGAAGFERHDAC8MAPT
SCHEMBL15567586 0.73 KIF11 (0.46) KDM4EGAAGFERHDAC8MAPT
SCHEMBL258911 0.73 GAA (1.00) KDM4EGAAGFERSCN2AIDO1
SCHEMBL29678302 0.72 TSHR (0.58) SCN2AIDO1HTR2CCTSSALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2885306-B1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE HOFFMANN LA ROCHE (CH) 2016-06-01 EP disclosed
EP-2885306-A1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE F. Hoffmann-La Roche AG (CH) 2015-06-24 EP disclosed
US-20150157739-A1 Imidazo[2,1]thiazol-3-one derivatives HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
WO-2014026881-A1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150157739-A1 Imidazo[2,1]thiazol-3-one derivatives MAPT, SNCA, PARK7 KDM4E 4876/4885GAA 588/4885GFER 3102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.